Lysosomal cysteine proteases: Structure, function and inhibition of cathepsins

Drug News and Perspectives

Volumn 18, Issue 10, 2005, Pages 605-614

  Roberts, Rebecca ^a  

^a URSINUS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLPHENYLALANYLALANYL FLUOROMETHYL KETONE; CA 030; CA 074; CATHEPSIN; CATHEPSIN B; CATHEPSIN F; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN O; CATHEPSIN S; CATHEPSIN V; CATHEPSIN W; CATHEPSIN X; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDYL PEPTIDASE I; LYSOSOME ENZYME; MORPHOLINEUREA LEUCINE HOMOPHENYLALANINE VINYLSULFONEPHENYL; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ALLERGY; ALZHEIMER DISEASE; ANTIGEN PRESENTATION; ARTHRITIS; ATHEROSCLEROSIS; BONE REMODELING; CANCER; CELL FUNCTION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME MECHANISM; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW;

CATHEPSINS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; HUMANS; LYSOSOMES;

EID: 33645094397     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.10.949485     Document Type: Review

References (111)

1. Stoka V., Turk, B. and Turk, V. Lysosomal cysteine proteases: Structural features and their role in apoptosis. IUBMB Life 2005, 57: 347-53.
2. Ishidoh, K. and Kominami, E. Processing and activation of lysosomal proteinases. Biol Chem 2002, 383: 1827-31.
3. Turk, D., Podobnik, M., Kuhelj, R., Dolinar, M. and Turk, V. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. FEBS Lett 1996, 384:211-4.
4. Bromme, D. and Kaleta, J. Thiol-dependent cathepsins: Pathophysiological implications and recent advances in inhibitor design. Curr Pharm Des 2002, 8: 1639-58.
5. Quraishi, O. and Storer, A.C. Identification of internal autoproteolytic cleavage sites within the prosegments of recombinant procathepsin B and procathepsin S. Contribution of a plausible unimolecular autoproteolytic event for the processing of zymogens belonging to the papain family. J Biol Chem 2001, 276: 8118-24.
6. Fox, T., de Miguel, E., Mort, J.S. and Storer, A.C. Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry 1992, 31: 12571-6.
7. Carmona, E., Dufour, E., Plouffe, C. et al. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases. Biochemistry 1996, 35: 8149-57.
8. Maehr, R., Hang, H.C., Mintern, J.D. et al. Asparagine endopeptidase is not essential for class IIMHC antigen presentation but is required for processing of cathepsin L in mice. J Immunol 2005, 174: 7066-74.
9. Ishidoh, K., Saido, T.C., Kawashima, S. et al. Multiple processing of procathepsin L to cathepsin L in vivo. Biochem Biophys Res Commun 1998, 252: 202-7.
10. Driessen, C., Bryant, R.A., Lennon-Dumenil, A.M. et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol 1999, 147: 775-90.
11. McQueney, M.S., Amegadzie, B.Y., D'Alessio, K. et al. Autocatalytic activation of human cathepsin K. J Biol Chem 1997, 272: 13955-60.
12. Rozman, J., Stojan, J., Kuhelj, R., Turk, V. and Turk, B. Autocalalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett 1999, 459: 358-62.
13. Mason, R.W., Gal, S. and Gottesman, M.M. The identification of the major excreted protein (MEP) from a transformed mouse fibroblast cell line as a catalytically active precursor form of cathepsin L. Biochem J 1987, 248: 449-54.
14. Musil, D., Zucic, D., Turk, D. et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: The structural basis for its specificity. EMBO J 1991, 10: 2321-30.
15. Zhao, B., Janson, C.A., Amegadzie, B.Y. et al. Crystal structure of human osteoclast cathepsin K complex with E-64. Nat Struct Biol 1997, 4: 109-11.
16. Guncar, G., Klemencic, I., Turk, B. et al. Crystal structure of cathepsin X: A flip-flop of the ring of His23 allows carboxymonopeptidase and carboxy-dipeptidase activity of the protease. Structure Fold Des 2000, 8: 305-13.
17. Somoza, J.R., Zhan, H., Bowman, K.K. et al. Crystal structure of human cathepsin V. Biochemistry 2000, 39: 12543-51.
18. Somoza, J.R., Palmer, J.T. and Ho, J.D. The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators. J Mol Biol 2002, 322: 559-68.
19. Pauly, T.A., Sulea, T., Ammirati, M. et al. Specificity determinants of human cathepsin S revealed by crystal structures of complexes. Biochemistry 2003, 42: 3203-13.
20. Schlechter I. and Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967, 27: 157-62.
21. Berger, A. and Schechter, I. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos Trans R Soc Lond B Biol Sci 1970, 257: 249-64.
22. Turk, D. and Guncar, G. Lysosomal cysteine proteases (cathepsins): Promising drug targets. Acta Crystallogr D Biol Crystallogr 2003, 59: 203-13.
23. Villadangos, J.A., Bryant, R.A., Deussing, J. et al. Proteases involved in MHC class II antigen presentation. Immunol Rev 1999, 172: 109-20.
24. Nakagawa, T., Roth, W., Wong, P. et al. Cathepsin L: Critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998, 280: 450-3.
25. Villadangos, J.A. and Ploegh, H.L. Proteolysis in MHC class II antigen presentation: Who's in charge? Immunity 2000, 12: 233-9.
26. Deussing, J., Roth, W., Saftig, P., Peters, C., Ploegh, H.L. and Villadangos, J.A. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci USA 1998, 95: 4516-21.
27. Katunuma, N., Matsunaga, Y., Himeno, K. and Hayashi, Y. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem 2003, 384: 883-90.
28. Manoury, B., Hewitt, E.W., Morrice, N., Dando, P.M., Barrett, A.J. and Watts, C. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 1998, 396: 695-9.
29. Driessen, C., Lennon-Dumenil, A.M. and Ploegh, H.L. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcgamma receptors. Eur J Immunol 2001, 31: 1592-601.
30. Antoniou, A.N., Blackwood, S.L., Mazzeo, D. and Watts, C. Control of antigen presentation by a single protease cleavage site. Immunity 2000, 12: 391-8.
31. Guncar, G, Podobnik, M., Pungercar, J., Strukelj, B., Turk, V. and Turk, D. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: Location of the minichain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Structure 1998, 6: 51-61.
32. Dodt, J. and Reichwein, J. Human cathepsin H: Deletion of the mini-chain switches substrate specificity from aminopeptidase to endopeptidase. Biol Chem 2003, 384: 1327-32.
33. Vasiljeva, O., Dolinar, M., Turk, V. and Turk, B. Recombinant human cathepsin H lacking the mini chain is an endopeptidase. Biochemistry 2003, 42: 13522-8.
34. Turk, B., Dolenc, I., Lenarcic, B. et al. Acidic pH as a physiological regulator of human cathepsin L activity. Eur J Biochem 1999, 259: 926-32.
35. Turk, B., Dolenc, I., Turk, V. and Bieth, J.G. Kinetics of the pH-induced inactivation of human cathepsin L. Biochemistry 1993, 32: 375-80.
36. Turk, B., Bieth, J.G., Bjork, I. et al. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol Chem Hoppe Seyler 1995, 376: 225-30.
37. Bromme, D., Okamoto, K., Wang, B.B. and Biroc, S. Human cathepsin O2 a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996, 271: 2126-32.
38. Gelb, B.D., Shi, GP, Chapman, H.A. and Desnick, R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273: 1236-8.
39. Song, J., Xu, P., Xiang, H., Su, Z., Storer, A.C. and Ni, F. The active-site residue Cys-29 is responsible for the neutral-pH inactivation and the refolding barrier of human cathepsin B. FEBS Lett 2000, 475: 157-62.
40. Kirschke, H., Wiederanders, B., Bromme, D. and Rinne, A. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem J 1989, 264: 467-73.
41. Pinitglang, S., Watts, A.B., Patel, M. et al. A classical enzyme active center motif lacks catalytic competence until modulated electrostatically. Biochemistry 1997, 36: 9968-82.
42. Troen, B.R. The role of cathepsin K in normal bone resorption. Drug News Perspect 2004, 17: 19-28.
43. Bromme, D. and Okamoto, K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995, 376: 379-84.
44. Inaoka, T., Bilbe, G, Ishibashi, O., Tezuka, K., Kumegawa, M. and Kokubo, T. Molecular cloning of human cDNA for cathepsin K: Novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995, 206: 89-96.
45. Wang, D., Li, W., Pechar, M., Kopeckova, P., Bromme, D. and Kopecek, J. Cathepsin K inhibitor-polymer conjugates: Potential drugs for the treatment of osteoporosis and rheumatoid arthritis. Int J Pharm 2004, 277: 73-9.
46. Garnero, P., Borel, O., Byrjalsen, I. et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998, 273: 32347-52.
47. Bossard, M.J., Tomaszek T.A., Thompson, S.K. et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 1996, 271: 12517-24.
48. Littlewood-Evans, A., Kokubo, T., Ishibashi, O. et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997, 20: 81-6.
49. Buck, M.R., Karustis, D.G, Day, N.A., Honn, K.V. and Sloane, B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992, 282(Pt 1): 273-8.
50. Felbor, U., Dreier, L., Bryant, R.A., Ploegh, H.L., Olsen, B.R. and Mothes, W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000, 19: 1187-94.
51. Abrahamson, M., Alvarez-Fernandez, M. and Nathanson, C.M. Cystatins. Biochem Soc Symp 2003: 179-99.
52. Lenarcic, B. and Bevec, T. Thyropins - New structurally related proteinase inhibitors. Biol Chem 1998, 379: 105-11.
53. Hart, T.C., Hart, P.S., Bowden, D.W. et al. Mutations of the cathepsin C gene are responsible for Papillon-Lefevre syndrome. J Med Genet 1999, 36: 881-7.
54. Toomes, C., James, J., Wood, A.J. et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet 1999, 23: 421-4.
55. Kominami, E., Ishido, K., Muno, D. and Sato, N. The primary structure and tissue distribution of cathepsin C. Biol Chem Hoppe Seyler 1992, 373: 367-73.
56. McGuire, M.J., Lipsky, P.E. and Thiele, D.L. Cloning and characterization of the cDNA encoding mouse dipeptidyl peptidase I (cathepsin C). Biochim Biophys Acta 1997, 1351: 267-73.
57. Pham, C.T. and Ley, T.J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci USA 1999, 96: 8627-32.
58. Riese, R.J., Wolf, P.R., Bromme, D. et al. Essential role for cathepsin S in MHC class Ç-associated invariant chain processing and peptide loading. Immunity 1996, 4: 357-66.
59. Riese, R.J., Mitchell, R.N., Villadangos, J.A. et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998, 101:2351-63.
60. Shi, GP, Bryant, R.A., Riese, R. et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000, 191: 1177-86.
61. Yasuda, Y., Kaleta, J. and Bromme, D. The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005, 57: 973-93.
62. Beck, H., Schwarz, G., Schroter, C.J. et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol 2001, 31: 3726-36.
63. Davis, G and Jeij, I. Modulation of experimental autoimmune encephalomyelitis (EAE) by a non-peptide inhibitor for cathepsin S. Inflamm Res 2002, 51: Abst A5.
64. Taleb, S., Lacasa, D., Bastard, J.P. et al. Cathepsin S, a novel biomarker of adiposity: Relevance to atherogenesis. FASEB J 2005, 19: 1540-2.
65. Liu, J., Sukhova, G.K., Yang, J.T. et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 2006, 184:302-11.
66. Liu, J., Sukhova, G.K., Sun, J.S., Xu, W.H., Libby, P. and Shi, G.P. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24: 1359-66.
67. Petanceska, S., Burke, S., Watson, S.J. and Devi, L. Differential distribution of messenger RNAs for cathepsins B, L and S in adult rat brain: An in situ hybridization study. Neuroscience 1994, 59: 729-38.
68. Munger, J.S., Haass, C., Lemere, C.A. et al. Lysosomal processing of amyloid precursor protein to A beta peptides: A distinct role for cathepsin S. Biochem J 1995, 311(Pt 1): 299-305.
69. Lemere, C.A., Munger, J.S., Shi, G.P. et al. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. Am J Pathol 1995, 146: 848-60.
70. Roth, W., Deussing, J., Botchkarev, V.A. et al. Cathepsin L deficiency as molecular defect of furless: Hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J 2000, 14: 2075-86.
71. Potts, W., Bowyer, J., Jones, H. et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 2004, 85: 85-96.
72. Hagemann, S., Gunther, T., Dennemarker, J. et al. The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol 2004, 83: 775-80.
73. Yasothornsrikul, S., Greenbaum, D., Medzihradszky, K.F. et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci USA 2003, 100: 9590-5.
74. Hook, V., Yasothornsrikul, S., Greenbaum, D. et al. Cathepsin L and Arg/Lys aminopeptidase: A distinct prohormone processing pathway for the biosynthesis of peptide neurotransmitters and hormones. Biol Chem 2004, 385: 473-80.
75. Joyce, J.A., Baruch, A., Chehade, K. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5: 443-53.
76. Sloane, B.F., Van, S., Podgorski, I. et al. Cathepsin B and tumor proteolysis: Contribution of the tumor microenvironment. Semin Cancer Biol 2005, 15: 149-57.
77. Agnantis, N.J., Goussia, A.C., Batistatou, A. and Stefanou, D. Tumor markers in cancer patients. An update of their prognostic significance. Part II. In Vivo 2004, 18: 481-8.
78. Skrzydlewska, E., Sulkowska, M., Wincewicz, A., Koda, M. and Sulkowski, S. Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer. World J Gastroenterol 2005, 11: 4225-9.
79. Trinkaus, M., Vranic, A., Dolenc, V.V. and Lah, T.T. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers 2005, 20: 50-9.
80. Lennon-Dumenil, A.M., Roberts, R.A., Valentijn, K. et al. The p41 isoform of invariant chain is a chaperone for cathepsin L. EMBO J 2001, 20: 4055-64.
81. Zavasnik-Bergant, V., Schweiger, A., Bevec, T., Golouh, R., Turk, V. and Kos, J. Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes. Immunology 2004, 112: 378-85.
82. Fiebiger, E., Maehr, R., Villadangos, J. et al. Invariant chain controls the activity of extracellular cathepsin L. J Exp Med 2002, 196: 1263-9.
83. Turk, B., Turk, D. and Turk, V. Lysosomal cysteine proteases: More than scavengers. Biochim Biophys Acta 2000, 1477: 98-111.
84. Leung-Toung, R., Li, W., Tam, T.F. and Karimian, K. Thiol-dependent enzymes and their inhibitors: A review. Curr Med Chem 2002, 9: 979-1002.
85. Bode, W. and Huber, R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 1992, 204: 433-51.
86. Wlodawer, A. and Gustchina, A. Structural and biochemical studies of retroviral proteases. Biochim Biophys Acta 2000, 1477: 16-34.
87. Aoyagi, T. and Umezawa, H. Proteases in Biological Control. E. Reich, D.B. Rifkin and E. Shaw (Eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1975.
88. Hanada, K., Tamai, M., Yamagishi, M., Ohmura, S., Sawada, J. and Tanaka, I. Agric Biol Chem 1978, 42: 523-8.
89. Varughese, K.I., Su, Y., Cromwell, D., Hasnain, S. and Xuong, N. H. Crystal structure of an actinidin-E-64 complex. Biochemistry 1992, 31: 5172-6.
90. Turk, D., Podobnik, M., Popovic, T. et al. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors. Biochemistry 1995, 34: 4791-7.
91. Klemencic, I., Carmona, A.K., Cezari, M.H. et al. Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase. Eur J Biochem 2000, 267: 5404-12.
92. Matsumoto, K., Mizoue, K., Kitamura, K., Tse, W.C., Huber, C.P. and Ishida, T. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers 1999, 51: 99-107.
93. Schaschke, N., Assfalg-Machleidt, I., Machleidt, W., Turk, D. and Moroder, L. E-64 analogues as inhibitors of cathepsin B. On the wie of the absolute configuration of the epoxysuccinyl group. Bioorg Med Chem 1997, 5: 1789-97.
94. Tsuge, H., Nishimura, T., Tada, Y. et al. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex. Biochem Biophys Res Commun 1999, 266: 411-6.
95. Drenth, J., Kalk, K.H. and Swen, H.M. Binding of chloromethyl ketone substrate analogues to crystalline papain. Biochemistry 1976, 15: 3731-8.
96. Jia, Z., Hasnain, S., Hirama, T. et al. Crystal structures of recombinant rat cathepsin B and a cathepsin B-inhibitor complex. Implications for structure-based inhibitor design. J Biol Chem 1995, 270: 5527-33.
97. Otto, H.H. and Schirmeister, T. Cysteine proteases and their inhibitors. Chem Rev 1997, 97: 133-72.
98. Rasnick, D. Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. Anal Biochem 1985, 149: 461-5.
99. Ahmed, N.K., Martin, L.A., Watts, L.M. et al. Peptidyl fluoromethyl ketones as inhibitors of cathepsin B. Implication for treatment of rheumatoid arthritis. Biochem Pharmacol 1992, 44: 1201-7.
100. Schotte, P., Schauvliege, R., Janssens, S. and Beyaert, R. The cathepsin B inhibitor z-FA.fmk inhibits cytokine production in macrophages stimulated by lipopolysaccharide. J Biol Chem 2001, 276:21153-7.
101. Albeck, A. and Kliper, S. Mechanism of cysteine protease inactivation by peptidyl epoxides. Biochem J 1997, 322(Pt 3): 879-84.
102. Palmer, J.T., Rasnick, D., Klaus, J.L. and Bromme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995, 38: 3193-6.
103. McGrath, M.E., Palmer, J.T., Bromme, D. and Somoza, J.R. Crystal structure of human cathepsin S. Protein Sci 1998, 7: 1294-302.
104. Bromme, D., Klaus, J.L., Okamoto, K., Rasnick, D. and Palmer, J.T. Peptidyl vinyl sulphones: A new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem J 1996, 315(Pt 1): 85-9.
105. Greenbaum, D., Medzihradszky, K.F., Burlingame, A. and Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 2000, 7: 569-81.
106. Greenbaum, D., Baruch, A., Hayrapetian. L. et al. Chemical approaches for functionally probing the proteome. Mol Cell Proteomics 2002, 1: 60-8.
107. Berger, A.B., Vitorino, P.M. and Bogyo. M. Activity-based protein profiling: Applications to biomarker discovery, in vivo imaging and drug discovery. Am J Pharmacogenomics 2004, 4: 371-81.
108. Lipper, R.A. How can we optimize selection of drug development candidates from many compounds at the discovery stage? Mod Drug Discov 1999, 2: 55-60.
109. Bogyo, M., Verfielst, S., Bellingard-Dubouchaud, V., Toba, S. and Greenbaum, D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem Biol 2000, 7: 27-38.
110. Rozman-Pungercar, J., Kopitar-Jerala, N., Bogyo, M. et al. Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: When reaction mechanism is more important than specificity. Cell Death Differ 2003, 10: 881-8.
111. Inoue, J., Nakamura, M., Cui, Y.S. et al. Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor. J Med Chem 2003, 46: 868-71.